



# OUR FUNDRAISING CAMPAIGN: TRANSFORMING HUMANITARIAN MEDICINE

GOAL MILLION EUROS

TOTAL RAISED

MILLION

EUROS

# 3 PRIORITY FUNDS: FINAL DISTRIBUTION OF FUNDS



EMERGENCY

6

6



RESEARCH
25%



TRAINING

100/

## 455 MAJOR DONORS SINCE 2016

	2016	2017	2018	2019	2020	2021
Total raised	€ 650 K	€ 908 K	€ 1 089 K	€ 1 470 K	€ 3 554 K	€ 2 682 K
Cumulated total	€ 650 K	€ 1558 K	€ 2 647 K	€ 4 117 K	€ 7 671 K	€ 10 353 K
% of final goal	6.5 %	16 %	26 %	41 %	<b>77</b> %	103 %

€ 10 354 162 raised = 103% of our goal



# ALIMAS EVOLUTION SINCE 2016



## YOUR IMPACT


Exploratory missions launched thanks to the emergency fund

Research projects incubated

Employees of ALIMA and partner NGOs obtained an advanced education diploma or certification

Indicator (Number of)	2016	2017	2018	2019	2020	2021
Exploratory Missions Launched	13	19	14	18	14	30
Emergency Interventions Launched	8	11	3	9	8	15
New Projects Opened	5	5	13	8	5	14
Total number of projects	31	31	42	38	67	55
Research projects incubated	3	5	8	10	5	8
Peer-review publications with ALIMA's contribution	8	4	5	4	4	7
Patients treated	642 486	880 621	1 064 053	1 368 751	1 739 834	1 493 091

# EVOLUTION OF FUNDRAISING IN ALIMA'S GLOBAL BUDGET




### ALIMA'S BUDGET


by source

- Annual budget
- Institutionnal donors
- Private donors

#### MILLION €










## DISTRIBUTION OF TOTAL RAISED by fund

	2016	2017	2018	2019	2020	2021
Emergency response fund	€ 464 K	€ 623 K	€ 649 K	€ 840 K	€ 2 457 K	€ 1 626 K
Research and innovation fund	€ 116 K	€ 201 K	€ 334 K	€ 439 K	€ 753 K	€ 772 K
Humanitarian talents fund	€ 70 K	€ 83 K	€ 106 K	€ 191 K	€ 344 K	€ 284 K
TOTAL BY YEAR	€ 650 K	€ 908 K	€ 1 089 K	€ 1 470 K	€ 3 554 K	€ 2 682 K

## FUNDRAISING EVOLUTION

over 6 years


- Cumulated
- Raised by year





## DISTRIBUTION OF FUNDS

by source



# EMERGENCY DESPONSE FUND GLOBAL CAMPAIGN REPORT ALIMA TRANSFORM HUMANITARIAN MEDICINE

# EMERGENCY RESPONSE FUND



#### **TOTAL RAISED 2016-2021**

E 6 658 MILLION





<sup>1</sup>The leverage effect is calculated as the ratio between the initial investment of the emergency fund (e.g., the first assessment mission) and the funding later obtained from institutional donors.

### **CHALLENGE**

To be able to deploy teams within 48 hours regardless of media attention or interest from institutional donors.

### **IMPACT**

To significantly reduce mortality in humanitarian emergencies and limit the spread of epidemics

	2016	2017	2018	2019	2020	2021
Investment from the emergency fund	€ 464 K	€ 623 K	€ 649 K	€ 840 K	€ 2 457 K	€ 1 626 K
Leverage effect	x 7.4	x 4.9	x 9	x 5	x 12	x 8.6
Raised	€ 3 425 000	€ 3 015 000	€ 5 887 049	€ 4 212 000	€ 29 371 535	€ 13 879 551

# 2021 EMERGENCY PROJECTS



YOUR DEDICATED CONTACT

Dr. Papys Lame, Head of ALIMA's


Medical Service

Projects	Emergency Fund investment	Total raised
Emergency life-saving medical care for people affected by the nutritional crisis in Katsina State (Nigeria)	€ 220 737	€ 1893685
Emergency assessment and rapid response to Ebola outbreak in Nzérékoré (Guinea)	€ 122 632	€ 1 744 701
Support of obstetric emergencies for displaced populations in South Kordofan (Sudan)	€ 223 631	€ 1 000 000
Assessment of the humanitarian situation with a focus on health and nutrition needs in Juba and Pibor County (South Sudan)	€ 168 667	0 *
Emergency life-saving medical care for the internally displaced persons and host population affected by the current crisis in Djugu, Ituri (DRC)	€ 337 333	€ 4 071 165
Deployment of Rapid Response Mechanism for COVID-19 outbreaks (Mali, Nigeria, CAR, DRC, Senegal, Sudan)	€ 553 000	€ 5 200 000
TOTAL	€ 1 626 000	€ 13 879 165

<sup>\*</sup> In South Sudan, ALIMA wasn't able to obtain further funding due to restrict financing.

## FOCUS: 2021 EMERGENCY PROJECTS






# RESEAR CHAND INNOVATION FUND

12

# RESEARCH AND INNOVATION FUND



#### **TOTAL RAISED 2016-2021**





<sup>&</sup>lt;sup>2</sup> The leverage effect is calculated as the ratio between the fund's initial investment and the funding obtained from institutional donors later on to incubate and develop the research project.

### **CHALLENGE**

To bring together researchers and frontline aid workers, leading to more relevant, innovative and sustainable solutions to humanitarian aid.

### **IMPACT**

To finance the initial phase of new research projects

	2016	2017	2018	2019	2020	2021
Investment from the emergency fund	€ 116 K	€ 201 K	€ 334 K	€ 439 K	€ 753 K	€ 773 K
Leverage effect	x 4.8	x 7.2	x 4.8	x 3.9	x 3.4	x 6
Raised	€ 551 330	€ 1 438 376	€ 1 610 701	€ 1 704 552	€ 2 500 580	€ 4 579 503

# 2021 RESEARCH AND INNOVATION PROJECTS




### YOUR DEDICATED CONTACT

**Dr. Marie Jaspard,** Coordinator of the emerging infectious diseases division of CORAL (Clinical and Operational Research Alliance)

Projects	Research fund investment	Total raised
OptiMA pilot study in Chad implementing the OptiMA protocol in 35 health centers in urban and rural districts to demonstrate its feasibility in different contexts	€ 137 922	€ 2 202 890
OptiMA randomized clinical trial in Niger comparing 2 simplified protocols for the management of malnutrition (OptiMA and COMPAS)	€ 176 525	€ 1 789 000
Capitalization and advocacy workshop linked to the OptiMA Bamako results	€ 25 624	€ 20 000
SAFARI phase II clinical randomized controlled trial testing Favipiravir as an alternate treatment to Lassa fever	€ 134 521	€ 150 000
COVERAGE trial aiming at testing potential treatments for asymptomatic, non-severe cases of COVID-19 to prevent deterioration of their condition	€ 201 515	€ 349 708
Development and deployment of the CUBE Lab, which allows for safer and more efficient testing of highly infectious samples from Ebola infected patients	€ 49 999	€ 30 000
Study under the ALLERT consortium (coordinated by the University of Oxford) to better understand hospitalized hemorrhagic fever cases and improve diagnosis	€ 46 961	€ 37 905
TOTAL	€ 773 067	€ 4 579 503

## FOCUS: 2021 RESEARCH AND INNOVATION PROJECTS





Following an advocacy and capitalization workshop organized after the results of the OptiMA Bamako study, the Malian Ministry of Health has committed to include an aspect of the simplified strategy - MUAC for Mothers - in its national protocol for screening and management of malnutrition.

SEYBA KEITA / ALIMA

The COVERAGE clinical trial aims to test potential treatments for asymptomatic, non-severe cases of COVID-19 to prevent a deterioration in their condition from worsening. The trial is part of a larger consortium of COVID-19 studies called ANTICOV led by DNDi (Drugs for Neglected Diseases Initiative).

© MOUNTAGA DRAME / ,

# IUMANITADIAN TALENTS FUND 16 GLOBAL CAMPAIGN REPORT ALIMA TRANSFORM HUMANITARIAN MEDICINE

# HUMANITARIAN TALENTS FUND



**TOTAL RAISED 2016-2021** 



### **CHALLENGE**

To train and provide a career path for our teams to improve the quality of our programs.

### **IMPACT**

To significantly increase the number of aid workers that receive capacity-building training.

	2016	2017	2018	2019	2020	2021
Talents fund investment	€ 70 K	€ 83 K	€ 106 K	€ 191 K	€ 344 K	€ 284 K
Estimated leverage effect	x2.2	x2.2	x 2.3	x 2.1	x 3	x 2.2
Estimated impact	€ 161 K	€ 190 K	€ 265 K	€ 407 K	€ 1 010 K	€ 624 K

<sup>&</sup>lt;sup>3</sup> Regarding the talent fund, it is difficult to evaluate the financial and human impact of the initial investment in training. The leverage effect is calculated by a mark-up index according to the level of training, the degree of skills acquired and the estimated impact on the quality of ALIMA projects.

# 2021 HUMANITARIAN TALENTS FUND PROJECTS




YOUR DEDICATED CONTACT
Marie Loro, Training Officer

Projects	Humanitarian talents fund investment	Estimated impact
Dedicated training weeks on Human Resources, Logistics and Finance for field and headquarters staff	€ 125 636	€ 251 271
Individual International Training Fund enabling ALIMA employees to access training courses leading to a diploma or certificate	€ 29 825	€ 149 126
Medical training week on pediatrics to improve identification of common syndromes and reduce mortality of hospitalized children (Chad)	€ 44 817	€ 134 451
Training on the proper use of the CUBE to 20 health workers during COVID-19 peaks (Senegal)	€ 38 905	€ 116 714
Elaboration of a Graduate Training Program on Viral Hemorrhagic Fevers, arboviruses, and other emerging epidemics in Africa between the Joseph Ki-Zerbo University (Burkina Faso) and Paris Sorbonne Nord University (France)	€ 44 817	€ 224 086
TOTAL	€ 284 000	€ 624 378

## FOCUS: 2021 HUMANITARIAN TALENTS FUND PROJECTS





# CAMPAIGN HIGHLIGHTS



## LAUNCH OF THE EUROPE COMMITTEE

In November, ALIMA officially launched
the first of its three Campaign Committees.
The European Committee was launched under
the presidency of Tidjane Dème and Serge Morelli
at an event held at the Partech offices, one of
the campaign supporters, in Paris.

## CELEBRATION OF ALIMA'S | 10TH ANNIVERSARY

In November, ALIMA celebrated ten years with a fundraising gala event at the Palais de Tokyo in Paris, and a fundraising event at the Salmagundi art club in New York alongside supporters of the "Transforming Humanitarian Medicine" campaign.

2017 — 2018

2019

## LAUNCH OF THE AFRICA COMMITTEE

In October, ALIMA held an event in Dakar to launch the Africa Campaign Committee under the presidency of Tidjane Dème and Madjiguène Sock. The event was part of the triple Dakar-Paris-New York celebration of ALIMA's 10 years of activity.

### YES AFRICAN

ALIMA's first brand awareness campaign,

"YES, AFRICAN," was launched in November
2020 to raise awareness and visibility

for ALIMA's unique working model.

2020 — 2021

## "TRANSFORMING HUMANITARIAN MEDICINE" CAMPAIGN CLOSING EVENT

On December 7, ALIMA ended its fundraising campaign with an event held simultaneously in Dakar, Paris, and New York. At the fundraisin gala, over € 1 million was raised and the goal of € 10 M in fundraising for the campaign was reached.

# OUR CAMPAIGN COMMITTEE

### **CAMPAIGN OFFICE**



PARIS

Hanna **SATSOU**DEVELOPMENT DIRECTOR
hanna.satsou@alima.ngo



**NEW YORK** 

Charlie **KUNZER**EXECUTIVE DIRECTOR ALIMA USA
charlie.kunzer@alima.ngo

### **EUROPE COMMITTEE**

Serge MORELLI, co-president
Tidjane Dème, co-president
Didier CHERPITEL
Georges DESVAUX
Anne-Marie IDRAC

Cathia LAWSON-HALL
Olivier RENAULT
Sandra SANCIER-SULTAN
Hervé SCHRICKE
Annick SCHWEBIG

### **ALIMA USA BOARD**

Elya TAGAR, President
Bernard YANCOVICH, Treasurer
Pierre CRÉMIEUX, Clerk
Catherine DUMAIT-HARPER
Anne-Catherine FAYE
Dr. Cecily GALLUP
Alan HARPER

Glenda HERSH
Charlie KUNZER,
Executive Director of ALIMA USA
Daniel GWINNELL
Julie ROUSSEAU
Dr. Alon UNGER

#### **AFRICA COMMITTEE**

Tidjane **DÈME**, co-president Madjiguène **SOCK**, co-president Barthélémy **FAYE** 

